Vertex Pharmaceuticals Incorporated (VRTX) Earnings History
Steady Earner35 years of earnings data (1991–2025) · Positive but moderate multi-year EPS trajectory
Loading earnings history...
Vertex Pharmaceuticals Incorporated (VRTX) Earnings Overview
As of June 21, 2026, Vertex Pharmaceuticals Incorporated (VRTX) reported trailing twelve-month net income of $4.34B, reflecting +836.5% year-over-year growth. The company earned $16.93 per diluted share over the past four quarters, with a net profit margin of 32.7%.
Looking at the long-term picture, VRTX's 5-year EPS compound annual growth rate (CAGR) stands at +8.3%, showing solid earnings momentum. The company achieved its highest annual net income of $3.95B in fiscal 2025, representing a new all-time high.
Vertex Pharmaceuticals Incorporated maintains industry-leading profitability with a gross margin of 85.0%, operating margin of 39.4%, and net margin of 32.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), ALNY ($577M net income, 8.4% margin), BMRN ($269M net income, 10.8% margin), VRTX has outperformed on profitability metrics. Compare VRTX vs REGN →
VRTX Earnings vs Peers
Earnings metrics vs comparable public companies
VRTX Historical Earnings Data (1991–2025)
35 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.95B | +838.1% | $4.76B | $15.32 | 32.7% | 39.4% |
| 2024 | -$536M | -114.8% | -$233M | $-2.08 | -4.9% | -2.1% |
| 2023 | $3.62B | +9.0% | $3.83B | $13.89 | 36.7% | 38.8% |
| 2022 | $3.32B | +41.8% | $4.31B | $12.82 | 37.2% | 48.2% |
| 2021 | $2.34B | -13.6% | $2.78B | $9.01 | 30.9% | 36.7% |
| 2020 | $2.71B | +130.4% | $2.86B | $10.29 | 43.7% | 46.0% |
| 2019 | $1.18B | -43.9% | $1.20B | $4.51 | 28.3% | 28.8% |
| 2018 | $2.10B | +695.8% | $635M | $8.09 | 68.8% | 20.8% |
| 2017 | $263M | +335.1% | $123M | $1.04 | 10.6% | 5.0% |
| 2016 | -$112M | +79.9% | $10M | $-0.46 | -6.6% | 0.6% |
| 2015 | -$558M | +24.4% | -$469M | $-2.31 | -54.1% | -45.4% |
| 2014 | -$739M | -66.0% | -$692M | $-3.14 | -127.2% | -119.3% |
| 2013 | -$445M | -315.8% | -$903M | $-1.98 | -36.7% | -74.5% |
| 2012 | -$107M | -461.9% | $2M | $-0.50 | -7.0% | 0.2% |
| 2011 | $30M | +103.9% | $114M | $0.14 | 2.1% | 8.1% |
| 2010 | -$755M | -17.6% | -$696M | $-3.77 | -526.3% | -485.5% |
| 2009 | -$642M | -39.5% | -$613M | $-3.70 | -628.7% | -601.1% |
| 2008 | -$460M | -17.5% | -$463M | $-3.27 | -262.0% | -263.6% |
| 2007 | -$391M | -89.1% | -$420M | $-3.03 | -196.6% | -210.9% |
| 2006 | -$207M | -1.7% | -$229M | $-1.83 | -95.6% | -105.9% |
| 2005 | -$203M | -22.4% | -$150M | $-2.28 | -126.4% | -93.2% |
| 2004 | -$166M | +15.5% | -$155M | $-2.12 | -161.8% | -150.7% |
| 2003 | -$197M | -81.2% | -$265M | $-2.56 | -284.6% | -382.6% |
| 2002 | -$109M | -64.0% | -$120M | $-1.43 | -67.4% | -74.2% |
| 2001 | -$66M | -67.0% | -$92M | $-0.89 | -39.5% | -54.8% |
| 2000 | -$40M | +3.3% | -$39M | $-0.59 | -50.8% | -49.5% |
| 1999 | -$41M | -23.9% | -$40M | $-0.80 | -66.6% | -64.3% |
| 1998 | -$33M | -67.2% | -$32M | $-0.65 | -74.5% | -73.0% |
| 1997 | -$20M | +50.5% | -$19M | $-0.41 | -45.2% | -43.8% |
| 1996 | -$40M | -86.0% | -$30M | $-1.07 | -300.8% | -224.1% |
| 1995 | -$22M | -22.2% | -$27M | $-0.63 | -97.3% | -119.9% |
| 1994 | -$18M | -980.0% | -$21M | $-0.56 | -89.8% | -105.6% |
| 1993 | $2M | +123.5% | $1M | $0.08 | 7.2% | 4.3% |
| 1992 | -$9M | -66.7% | -$10M | $-0.35 | -223.7% | -263.2% |
| 1991 | -$5M | - | -$6M | $-0.35 | -159.4% | -175.0% |
Download Data
Export VRTX earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into VRTX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
35+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VRTX — Frequently Asked Questions
Quick answers to the most common questions about buying VRTX stock.
What is VRTX earnings per share (EPS)?
VRTX trailing twelve-month (TTM) diluted EPS is $16.93, reflecting +836.5% year-over-year growth. The 5-year EPS CAGR is +8.3%. Complete EPS history from 1991 to 2025 is available in the table on this page.
What is Vertex Pharmaceuticals Incorporated's net income?
Vertex Pharmaceuticals Incorporated (VRTX) trailing twelve-month net income is $4.3B as of 2025. Earnings grew +836.5% year-over-year.
Is VRTX profitable?
Yes, VRTX is profitable with a TTM net income of $4.3B and a net profit margin of +32.7%.
What is VRTX's earnings growth rate?
VRTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: +6.1%, 5-Year: +8.3%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1991 to 2025.
What are VRTX's profit margins?
Vertex Pharmaceuticals Incorporated net profit margin is +32.7%, operating margin is +39.4%, and gross margin is +85.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +22.5%.
Is VRTX growing earnings?
Yes, VRTX earnings are accelerating — EPS growth of +836.5% exceeds the 5-year CAGR of +8.3%. TTM net income reached $4.3B. Earnings momentum is strengthening.
What was VRTX's best earnings year?
Vertex Pharmaceuticals Incorporated's highest annual net income on record is $4.0B, achieved in fiscal year 2025. Earnings history on this page spans 1991 to 2025 and includes all annual and quarterly figures.
What were VRTX's earnings last quarter?
VRTX's most recent reported quarter was Q1 2026. Net income was $1.0B with diluted EPS of $4.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.